Evidence map›Paper›PMID 31811340›Full record

ReviewWorld journal of surgery2020

Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy.

James Sun, Dennis A Kirichenko, Joyce L Chung, Michael J Carr, Zeynep Eroglu, Nikhil I Khushalani, Joseph Markowitz, Jane L Messina, Vernon K Sondak, Jonathan S Zager and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Employment, work ability and sick leave in melanoma patients within the first year of diagnosis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Observational
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

James SunDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0002-9915-6974
Dennis A KirichenkoMorsani College of Medicine, University of South Florida, Tampa, FL, USA.
Joyce L ChungMorsani College of Medicine, University of South Florida, Tampa, FL, USA.
Michael J CarrDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Zeynep ErogluDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Nikhil I KhushalaniDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Joseph MarkowitzDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Jane L MessinaDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Vernon K SondakDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Jonathan S ZagerDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Sephalie Y PatelDepartment of Anesthesiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA. Sephalie.Patel@Moffitt.org.
Moffitt Cancer Center · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTraditional chemotherapy agents adversely affect wound healing and need to be held prior to or after surgery. Immune checkpoint inhibitors (ICIs) and targeted agents are now standard of care for the several treatment cancers. We hypothesize that ICI and targeted therapy do not have similar adverse effects on perioperative outcomes.

methodsWe performed a review of melanoma patients undergoing surgery at an academic hospital between 2011 and 2019. All patients received ICI or targeted therapy ≤ 60 days prior to surgery, including palliative procedures. Preoperative performance status was assessed using Eastern Cooperative Oncology Group score and American Society of Anesthesiologists Classification System. Thirty-day complications were classified by Clavien-Dindo grade. No statistical comparisons were performed.

resultsOf 63 patients included in the analysis, 29 (46%) patients received ICI and 34 (54%) received targeted therapy with median of 14 days (IQR 5-27 days) between the last preoperative dose and day of surgery (ICI, median 18 days [IQR 13-34.5]; targeted therapy, median 7 days [IQR 3-22.25]). There were no perioperative mortalities. Among patients treated with ICI, 22 patients (76%) had no complications. Four patients had wound infections (2 readmitted), 1 had reoperation (hematoma) and 2 readmitted for other reasons (fever; volvulus). Among patients treated with targeted therapy, 25 patients (74%) had no complications. Seven patients had wound infections (none readmitted), 1 had reoperation (flap failure) and 1 had dehiscence (not treated).

conclusionsPatients undergoing treatment with ICI or targeted therapies can safely undergo surgery without substantially increased risk of serious intraoperative and postoperative complications.

Indexed as

Molecular Targeted TherapyAdolescentAdultAgedAged, 80 and overChildCombined Modality TherapyFemaleHumansImmune Checkpoint InhibitorsMaleMelanomaMiddle AgedPostoperative ComplicationsReoperationRetrospective StudiesImmune Checkpoint Inhibitors

Identifiers

PMID31811340
OpenAlexW2992766279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.